Low-molecular-weight heparins and angiogenesis

APMIS

Volumn 114, Issue 2, 2006, Pages 79-102

  Norrby, Klas ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiogenesis; Angiogenic growth factors; Anti angiogenesis; Antiangiogenic growth factors; Dalteparin; Endothelial cells; Heparin; Heparin molecular mass; Heparin binding growth factors; Low molecular weight heparin; Tinzaparin

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTITHROMBIN; BEVACIZUMAB; CERTOPARIN; DALTEPARIN; ENOXAPARIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; FONDAPARINUX; HEPARAN SULFATE; HEPARIN; HEPARIN COFACTOR II; HYDROCORTISONE; IRINOTECAN; LOW MOLECULAR WEIGHT HEPARIN; OLIGOSACCHARIDE; POLYSACCHARIDE; PROSTACYCLIN; PROTEIN TYROSINE KINASE INHIBITOR; REVIPARIN; SEMAXANIB; SERINE PROTEINASE INHIBITOR; STEROID; THROMBOCYTE FACTOR 4; TINZAPARIN; TISSUE FACTOR PATHWAY INHIBITOR; UNINDEXED DRUG;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; ARTERY THROMBOSIS; BLEEDING; BLOOD CLOTTING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOVASCULAR SYSTEM; CELL FUNCTION; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG HALF LIFE; EVOLUTIONARY ADAPTATION; HEART INFARCTION; HUMAN; HYPERCOAGULABILITY; IN VITRO STUDY; IN VIVO CULTURE; IN VIVO STUDY; LUNG EMBOLISM; METASTASIS; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SURVIVAL TIME; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT; VASCULAR ENDOTHELIUM; VENOUS THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; ANIMALS; CLINICAL TRIALS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 33644830185     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2006.apm_235.x     Document Type: Review

References (154)

1. Boccaccio C Sabatino G Medico E Girolami F Follenzi A Reato G Sottile A Naldini L Comoglio PM The MET oncogene drives a genetic programme linking cancer to haemostasis Nature 2005 434 396 400
2. Yu JL May L Lhotak V Shahrzad S Shirasawa S Weitz JI Coomber BL Mackman N Rak JW Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis Blood 2005 105 1734 41
3. Mousa SA Low-molecular-weight heparin in thrombosis and cancer Semin Thromb Hemost 2004 30 Suppl 1 25 30
4. Wojtukiewicz MZ Sierko E Zacharski LR Interfering with hemostatic system components: possible new approaches to anti-angiogenic therapy Sem Thrombos Hemost 2004 30 145 56
5. Schulman S Lindmarker P Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism N Engl J Med 2000 342 1953 8
6. Miller GJ Bauer KA Howarth DJ Cooper JA Humphries SE Rosenberg RD Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway J Thromb Haemost 2004 2 2107 14
7. Castelli R Porro F Tarsia P The heparins and cancer: review of clinical trials and biological properties Vasc Med 2004 9 205 13
8. Hirsh J Raschke R Heparin and low-molecular-weight heparin Chest 2004 126 Suppl. 3 188S 203S
9. Tyrrell DJ Kilfeather S Page CP Therapeutic uses of heparin beyond its traditional role as an anti-coagulant TiPS 1995 16 198 204
10. Eslin DE Zhang C Samuels KJ Rauova L Zhai L Niewiarowski S Cines DB Poncz M Kowalska MA Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anti-coagulant and anti-thrombotic effect of heparin Blood 2004 104 3173 80
11. D'Amore PA Heparin-endothelial cell interactions Haemoatasis 1990 20 Suppl 1 159 65
12. Salbach PB Brückmann M Turovets O Kreuzer J Kübler W Walter-Sack I Heparin-mediated selective release of hepatocyte growth factor in humans J Clin Pharmacol 2000 50 221 6
13. Léculier C Couprie N Adeleine P L'etienne P Francina A Richard M The effects of high molecular weight- and low molecular weight-heparins on superoxide ion production and degranulation by human polymorphonuclear leukocytes Thromb Res 1993 69 519 31
14. Zacharski LR Ornstein DL Heparin and cancer Thomb Haemost 1998 80 10 23
15. Maulik N Das DK Redox signaling in vascular angiogenesis Free Rad Biol Med 2002 33 1047 60
16. Schäfer G Cramer T Suske G Kemmner W Wiedenmann B Höcker M Oxidative stress regulated vascular endothelial growth factor-A gene transcription through Sp1- and Sp3-dependent activation of two proximal GC-rich promoter elements J Biol Chem 2003 278 8190 8
17. Albertsson P Lennernäs B Norrby K On metronomic chemotherapy: modulation of angiogenesis mediated by VEGF-A Acta Oncol 2006 in press
18. Fareed J Leong WL Hoppensteadt DA Jeske WP Walenga J Wahi R Bick RL Generic low-molecular-weight heparins: some practical considerations Semin Thromb Hemost 2004 30 703 13
19. Lopez LM Low-molecular-weight heparins are essentially the same for treatment and prevention of venous thromboembolism Pharmacother 2001 21 56S 61S
20. Morris TA Jacobson A Marsh JJ Lane JR Pharmacokinetics of UFH and LMWH are similar with respect to anti-thrombin activity Thromb Res 2005 115 45 51
21. Mousa SA The low molecular weight heparin, tinzaparin, in thrombosis and beyond Cardiovasc Drug Rev 2002 20 199 216
22. Cheer SM Dunn CJ Foster R Tinzaparin sodium. A review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease Drugs 2004 64 1479 502
23. Quinlan DJ McQuillan A Eikelboom JW Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism. A meta-analysis of randomized controlled trials Ann Intern Med 2004 140 175 83
24. Horton J Venous thrombotic events in cancer: the bottom line Cancer Control 2005 12 31 7
25. Norman M Norrby K Tumour cell volume changes in vivo induced by heparin Pathol Eur 1971 6 268 77
26. Hirsh J Warkentin TE Shaughnessy SG Anand SS Halperin JL Raschke R Granger C Ohman EM Dalen JE Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety Chest 2001 119 64S 94S
27. Pinhal MAS Trindade ES Fareed J Dietrich CP Nader HB Heparin and a cyclic octaphenol-octasulfonic acid (GL-522-Y-1) bind with high affinity to a 47-kDa protein from vascular endothelial cell surface and stimulate the synthesis and structural changes of heparan sulfate proteoglycan Thromb Res 2001 103 35 45
28. Tiozzo R Cingi MR Croce MA Interaction of heparan sulfate and its fractions with endothelial cells in culture Int J Tiss Reac 1993 15 163 8
29. Patton WA Granzow CA Getts LA Thomas SC Zotter LM Gunzel KA Lowe-Krentz LJ Identification of a heparin-binding protein using monoclonal anti-bodies that block heparin binding to porcine aortic endothelial cells Biochem J 1995 311 461 9
30. Kuwahara-Watanabe K Hidai C Ikeda H Aoka Y Ichikawa K Iguchi N Okada-Ohno M Yokota J Kasanuki H Kawana M Heparin regulates transcription of endothelin-1 gene in endothelial cells J Vasc Res 2005 42 183 9
31. Colin S Jeanny JC Mascarelli F Vienet R Al-Mahmood S Courtois Y Labarre J In vivo involvement of heparan sulfate proteoglycan in the bioavailablity, internalization, and catabolism of exogenous basic fibroblast growth factor Mol Pharmacol 199 55 74 82
32. Fareed J Jeske W Hoppensteadt D Clarizio R Walenga JM Are the available low-molecular-weight heparin preparations the same? Sem Thromb Hemost 1996 22 Suppl 1 77 91
33. Folkman J Angiogenesis in cancer, vascular, rheumatic and other diseases Nat Med 1995 1 27 31
34. Hanahan D Weinberg RA The hallmarks of cancer Cell 2000 100 57 70
35. Vermeulen PB Gasparini G Fox SB Colpaert C Marson LP Gion M Beliën JAM de Waal RMW Van Marck E Magnani E Weidner N Harris AL Dirix LY Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours E J Cancer 2002 8 1564 79
36. Folkman J Tumor angiogenesis: therapeutic implications N Engl J Med 1971 285 1182 6
37. Ivan M Kondo K Yang H Kim W Valiando J Ohh M Salic A Asara JM Lane WS Kaelin WG HIF alpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing Science 2001 292 464 8
38. Stein I Keshet E Regulation of vascular endothelial growth factor (VEGF) expression In Voest E E, D'Amore P A, editors Tumor angiogenesis and Microcirculation New York Marcel Dekker 2001 213 26
39. Carmeliet P Jain RK Angiogenesis in cancer and other diseases Nature 2000 407 249 57
40. Ferrara N The role of vascular endothelial growth factor in angiogenesis In Rubanyi GM, editor Angiogenesis in Health and Disease. Basic mechanisms and clinical applications New York Marcel Dekker 2000 47 73
41. Affara NI Robertson FM Vascular endothelial growth factor as a survival factor in tumor-associated angiogenesis In Vivo 2004 18 525 42
42. Hurwitz H Fehrenbacher L Novotny W Cartweight T Hainsworth J Heim W Berlin J Baron A Griffing S Holmgren E Ferrara N Fyfe G Rogers B Ross R Kabbinavar F Bevacizumab plus irinotecan, fluoruracil, and leucovorin for metastatic colorectal cancer N Engl J Med 2004 230 2335 42
43. Ellis LM Bevacizumab Nat Rev Drug Discov 2005 Suppl S8 9
44. Browder T Butterfield CE Kraling BM Shi B Marshall B O'Reilly MS Folkman J Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer Res 2000 60 1878 86
45. Klement G Baruchel S Rak Man S Clarke K Hicklin DJ Bohlen P Kerbel RS Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity J Clin Invest 2000 105 R15 R24
46. Klement G Huang P Mayer B Green SK Man S Bohlen P Hicklin D Kerbel RS Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGF-2 antibody in multidrug-resistant human breast cancer xenografts Clin Cancer Res 2002 8 221 32
47. Kerbel RS Kamen BA The anti-angiogenic basis of metronomic chemotherapy Nat Rev 2004 4 423 36
48. Pietras K Hanahan D A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen in antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer J Clin Oncol 2005 23 939 52
49. Bobek V Kovarik J Anti-tumor and anti-metastatic effects of warfarin and heparins Biomed Pharmacother 2004 58 213 9
50. Hagmar B Norrby K Evidence for effects on cell surfaces influencing experimental metastases Int J Cancer 1970 5 72 84
51. Sciumbata T Caretto P Pirovano P Pozzi P Cremonesi P Galimberti G Leoni F Marcucci F Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival Invasion Metastasis 1996 16 132 43
52. Zacharski LR Ornstein DL Mamourian AC Low-molecular-weight heparin and cancer Semin Thromb Hemost 2000 26 Suppl 1 69 77
53. Ono K Ishihara M Ishikawa K Ozeki Y Deguchi H Sato M Hashimoto H Saito Y Yura H Kurita A Maehara T Periodate-treated non-anti-coagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung Br J Cancer 2002 86 1803 12
54. Amirkhosravi A Mousa SA Amaya M Francis JL Anti-metastatic effect of tinzaparin, a low-molecular-weight heparin J Thromb Haemost 2003 1 1972 6
55. Yoshitomi Y Nakaniski H Kusano Y Munesue S Oguri K Tatematsu M Yamashina I Okayama M Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anti-coagulant activity Cancer Lett 2004 207 165 74
56. Smorenburg SM Van Noorden CJ The complex effects of heparins on cancer progression and metastasis in experimental studies Pharmacol Rev 2001 53 91 105
57. Vlodavsky I Goldshmidt O Properties and function of heparanase in cancer metastasis and angiogenesis Haemost 2001 31 Suppl 1 60 3
58. Pross M Lippert H Nestler G Kuhn R Langer H Mantke R Schulz HU Effect of low molecular weight heparin on intra-abdominal metastasis in a laparoscopic experimental study Int J Colorec 2004 19 143 6
59. Kakkar AK Low-molecular-weight heparin and survival inn patients with malignant disease Cancer Control 2005 12 Suppl 1 22 30
60. Green D Hull RD Brant R Pineo GF Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin Lancet 1992 339 1476
61. Hull RD Raskob GE Pineo GF Green D Trowbridge AA Elliot CG Lerner RG Hall J Sparling T Brettell HR Norton J Carter CJ George R Merli G Ward J Mayo W Rosenbloom D Brant R Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis N Engl J Med 1992 326 975 82
62. Siragusa S Cosmi B Piovella F Hirsh J Ginsberg JS Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis Am J Med 1996 100 269 77
63. Simonneau G Sors H Charbonnier B Page Y Laaban J-P Azarian R Laurent M Hirsch J-L Ferrari E Bosson J-L Mottier D Beau B A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism N Engl J Med 1997 337 663 9
64. Hettiarachchi RJK Smorenburg SM Ginsberg J Levine M Prins MH Büller HR Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread Thromb Haemost 1999 82 947 52
65. Prandoni P Piccioli A Girolami A Cancer and venous thromboembolism: an overview Haematologica 1999 84 437 45
66. Altinbas M Coskun HS Er O Ozkan M Eser B Unal A Cetin M Soyuer S A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer J Thromb Haemost 2004 2 1266 71
67. Falanga A The effect of anti-coagulant drugs on cancer J Thromb Haemost 2004 2 1263 5
68. Kakkar AK Levine MN Kadziola Z Lemoine NR Low V Patel HK Rustin G Thomas M Quigley M Williamson RCN Low molecular weight heparin, therapy with dalteparin and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS) J Clin Oncol 2004 22 1944 8
69. Klerk CPW Smorenburg SM Otten H-M Lensing AWA Prins MH Piovella F Prandoni P Bos MMEM Richel DJ van Tienhoven G Büller HR The effect of low molecular weight heparin on survival in patients with advanced malignancy J Clin Oncol 2005 23 2130 5
70. Lee AY Rickles FR Julian JA Gent M Baker RI Bowden C Kakkar AK Prins M Levine MN Randomized comparison of low molecular weight heparin and coumarin derivatives of the survival of patients with cancer and venous thromboembolism J Clin Oncol 2005 23 2123 9
71. von Tempelhoff G-F Harenberg J Niemann F Hommel G Kirkpatrick CJ Heilmann L Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvis cancer surgery: a prospective randomized double-blind trial Int J Oncol 2000 16 815 24
72. Maia RC Wagner K Cabral RH Rumjanek VM Heparin reverses Rhodamine 123 extrusion by multidrug resistant cells Cancer Lett 1996 106 101 8
73. Degen JL Massari JV Talmage KE La Jeunesse CM Kombrinck KW Flick MJ Palumbo JS Hemostatic factors support metastasis by impeding NK cell-mediated elimination of embolic tumor cells Haematologica Reports 2005 1 issue 9 21 3
74. Bobek V Boubelik M Fiserova A L'Uptovcova M Vannucci L Kacprzak G Kolodezej J Majewski AM Hoffman RM Anti-coagulant drugs increase natural killer cell activity in lung cancer Lung Cancer 2005 47 215 23
75. Mechtcheriakova D Wlachos A Holzmuller H Binder BR Hofer E Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1 Blood 1999 93 3811 23
76. Kim I Oh JL Ryu YS So JN Sessa WC Walsh K Koh GY Angiopoietin-1 negatively regulates expression and activity of tissue factor in endothelial cells FASEB J 2002 16 126 8
77. Couglin SR Thrombin signaling and protease-activated receptors Nature 2000 407 258 64
78. Ruf W Tissue factor-PAR2 signaling crosstalk in cancer and angiogenesis Haematologica Reports 2005 1 issue 9 15 7
79. Nierodzik M Plotkin A Kajumo F Karpatkin S Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo J Clin Invest 1991 87 229 36
80. Caunt M Huang YQ Brooks PC Karpatkin S Thrombin induces neoangiogenesis in the chick chorioallantoic membrane J Thromb Haemost 2003 1 2097 102
81. Karpatkin S Cytokine GRO-alpha is pivotal in thrombin-induced angiogenesis Haematologica Reports 2005 1 issue 9 25 6
82. Kinoshita M Miyamoto T Ohashi N Sasayama S Matsumori A Thrombosis increases circulatory hepatocyte growth factor by degranulation of mast cells Circulation 2002 106 3133 8
83. Norrby K Mast cells and angiogenesis APMIS 2002 110 355 71
84. Matsumori A Roles of hepatocyte growth factor and mast cells in thrombosis and angiogenesis Cardiovasc Drugs Ther 2004 18 321 6
85. Bikfalvi A Platelet factor 4: an inhibitor of angiogenesis Semin Thromb Hemost 2004 30 379 85
86. Zhang Y Deng Y Luther T Muller M Ziegler R Waldherr R Stern DM Nawroth PP Tissue factor controls the balance of angiogenic and anti-angiogenic properties of tumor cells in mice J Clin Invest 1994 94 1320 7
87. Ruf W Mueller BM Tissue factor in cancer angiogenesis and metastasis Curr Opin Hematol 1996 3 379 84
88. Mechtcheriakova D Schabbauer G Lucerna M Clauss M de Martin R Binder BR Hofer E Specificity, diversity, and convergence in VEGF and TNF-alpha signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells FASEB J 2001 15 230 42
89. Fernandez PM Patierno SR Rickles FR Tissue factor and fibrin in tumor angiogenesis Semin Thromb Hemost 2004 30 31 44
90. Belting M Dorrell MI Sandgren S Aguilar E Ahamed J Dorfleutner A Carmeliet P Mueller BM Friedlander M Ruf W Regulation of angiogenesis by tissue factor cytoplasmic domain signaling Nat Med 2004 10 502 9
91. Abbate R Gori AM Modesto PA Attanasio M Martini F Colella A Giusti B Cecioni I Neri Serneri GG Heparin, monocytes, and procoagulant activity Haemostasis 1990 20 Suppl 2 98 100
92. Wun TC Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor heparin: synergistic anti-coagulant action between LACI and sulfated polysaccharides Blood 1992 79 430 8
93. Jeske W Fareed J Eschenfelder V Iqbal O Hoppensteadt D Ahsan A Biochemical and pharmacologic characteristics of Reviparin, a low-molecular-mass heparin Semin Thrombos Hemostas 1997 23 119 28
94. Pepe G Guisti B Attanasio M Gori AM Comeglio P Martini F Gensini G Abbate R Neri Serneri GG Tissue factor and plasminogen activator inhibitor type 2 expression in human stimulated monocytes is inhibited by heparin Semin Thrombos Hemostas 1997 23 135 41
95. Fareed J Fu K Yang LH Hoppensteadt DA Pharmacokinetics of low molecular weight heparins in animal models Semin Thromb Hemost 1999 25 Suppl 3 51 5
96. Pu LL Holme KR Symes JF Heparinase enhances collateral vessel development in the ischemic limb Int Surg 2002 87 260 8
97. Boyd DD Nakajima M Involvement of heparanase in tumor metastases: a new target in cancer therapy? J Natl Cancer Inst 2004 96 1194 5
98. Edovitsky E Elkin M Zcharia E Peretz T Vlodavsky I Heparanase gene slicing, tumor invasivess, angiogenesis, and metastasis J Natl Cancer Inst 2004 96 1219 30
99. Vlodavsky I Friedman Y Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis J Clin Invest 2001 108 341 7
100. Gingis-Velitski S Zetser A Flugelman MY Vlodavsky I Heparanase induces endothelial cell migration via protein kinase B/Akt activation J Biol Chem 2004 279 23536 41
101. El-Assal ON Yamanoi A Ono T Kohno H Nagasue N The clinicopathological significance of heparanase and basic fibroblast growth factor expression in hepatocellular carcinoma Clin Cancer Res 2001 7 1299 305
102. Mikami S Ohashi K Katsube K Nemoto T Nakajima M Okada Y Coexpression of heparanase, basic fibrobast growth factor and vascular endothelial growth factor in human esophageal carcinoma Pathol Int 2004 54 556 63
103. Vlodavsky I Ilan N Abboud-Jarrous G Nadir Y Brenner B Naggi A Pisano C Casu B The impact of heparanase on cancer progression Haematologica Reports 2005 1 issue 9 61 2
104. Murray JC Angiogenesis Protocols. Methods in molecular medicine New Jersey Humana Press 2001
105. Norrby K Angiogenesis: new aspects relating to its initiation and control APMIS 1997 105 417 37
106. Norrby K Microvascular density in terms of number and length of microvessel segments per unit tissue volume in mammalian angiogenesis Microvasc Res 1998 55 43 53
107. 165-mediated angiogenesis in the rat Int J Cancer 2001 91 236 40
108. Albertsson P Lennernäs B Norrby K Chemotherapy and anti-angiogenesis: drug-specific effects on microvessel sprouting APMIS 2003 111 995 1003
109. Norrby K Basic fibroblast growth factor and de novo mammalian angiogenesis Microvasc Res 1994 48 96 113
110. Norrby K Vascular endothelial growth factor and mammalian angiogenesis Microvasc Res 1996 51 154 63
111. Fidler IJ Ellis LM Chemotherapeutic drugs - more really is not better Nat Med 2000 6 500 2
112. Kerbel RS Tumor angiogenesis: past, present and the near future Carcinogen 2000 21 505 15
113. Norrby K Jakobsson A Sorbo J Mast-cell-mediated angiogenesis: a novel experimental model using the rat mesentery Virchows Arch B Cell Pathol Incl Mol Pathol 1986 52 195 206
114. Mattsby-Baltzer I Jakobsson A Sörbo J Norrby K Endotoxin is angiogenic Int J Exp Pathol 1994 75 191 6
115. Norrby K Sörbo J Heparin enhances angiogenesis by a systemic mode of action Int J Exp Pathol 1992 73 147 55
116. Norrby K Heparin and angiogenesis: a low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically Haemostasis 1993 23 Suppl 1 141 9
117. Norrby K Østergaard P Basic-fibroblast-growth factor-mediated de novo angiogenesis is more effectively suppressed by low-molecular-weight than by high-molecular-weight heparin Int J Microcirc Clin Exp 1996 16 8 15
118. 165-mediated angiogenesis Int J Microcirc 1997 17 314 21
119. 165-mediated mammalian angiogenesis Int J Exp Path 2000 81 191 8
120. 165 to its receptors Biochem Biophys Res Commun 1994 203 1339 47
121. Mousa SA Mohamed S Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anti-cancer efficacy Oncol Rep 2004 12 683 8
122. Mousa SA Mohamed S Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor Thromb Haemost 2004 92 627 33
123. Mousa SA Anti-angiogenesis effect of low molecular weight heparin is primarily mediated by tissue factor pathway inhibitor Haematologica Reports 2005 1 issue 9 Poster 91 111
124. Chabut D Fischer A-M Colliec-Jouault S Laurendeau I Matou S Le Bonniec B Helley D Low molecular weight fucoidan and heparin enhances the basic fibroblast growth factor-induced tube formation of endothelial cells through heparan sulfate-dependent alpha6 overexpression Mol Pharmacol 2003 64 696 702
125. Fernandez PM Chou DS Aquilina JW Patierno SR Rickles FR Unfractionated heparin (UFH) and a low molecular weight heparin (dalteparin) exhibit anti-angiogenic effects using in vitro, ex vivo and in vivo angiogenesis models Proc Am Assoc Cancer Res 2003 94 Meeting 698 9
126. Jörneskog G Brismar K Fagrell B Low molecular weight heparin seems to improve local capillary circulation and healing of chronic foot ulcers in diabetic patients VASA 1993 22 137 42
127. Quyyumi A Diodati JG Lakatos E Bonow RO Epstein SE Angiogenic effects of low molecular weight heparin in patients with stable coronary artery disease: a pilot study JACC 1993 22 635 41
128. Norrby K Nordenhem A VEGF-A-mediated angiogenesis in vivo: dalteparin stimulates and epirubicin insignificantly affects angiogenesis following metronomic treatment, while the combination of the two significantly inhibits it Haematologica Reports 2005 1 issue 9 poster 102 115
129. Takahashi H Ebihara S Okazaki T Asada M Sasaki H Yamaya M A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity Br J Pharmacol 2005 146 333 43
130. Collen A Smorenburg SM Peters E Lupu F Koolwijk P Van Noorden C van Hinsbergh VWM Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro Cancer Res 2000 60 6196 200
131. Smorenburg SM Vink R te Lintelo M Tigchelaar W Maas A Büller HR Van Noorden CJF In vivo treatment of rats with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) does not affect experimentally induced colon carcinoma metastasis Clin Exp Metast 1999 17 451 56
132. Hlatky L Hahnfeldt P Folkman J Clinical application of anti-angiogenic therapy: microvessel density, what it does and doesn't tell us J Natl Cancer Inst 2002 94 883 90
133. Kerbel RS Klement G Prichard KI Kamen B Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic Ann Oncol 2002 13 12 5
134. Lennernäs B Albertsson P Damber J-E Norrby K Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals: a quantitative study APMIS 2004 112 201 9
135. Khorana AA Sahni A Altland OD Francis CW Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight Arterioscl Thromb Vasc Biol 2003 23 2110 5
136. Crum R Szabo S Folkman J A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment Science 1985 230 1375 8
137. Folkman J Weisz PB Joullié MM Li WW Ewing WR Control of angiogenesis with synthetic heparin substitutes Science 1989 243 1490 3
138. Folkman J Shing Y Control of angiogenesis by heparin and other sulfated polysaccharides Adv Exp Med Biol 1992 313 355 64
139. Thorpe PE Derbyshire EJ Andrade SP Press N Knowles PP King S Watson HJ Yang YC Rao-Bette M Heparin-steroid conjugates: new angiogenesis inhibitors with anti-tumor activity in mice Cancer Res 1993 53 3000 7
140. Derbyshire EJ Comin GA Yang YC Overholster J Watkins L Thorpe PE Anti-tumor and anti-angiogenic effects in mice of heparin conjugated to angiostatic steroids Int J Cancer 1995 63 694 701
141. Lepri A Benelli U Bernardini N Bianchi F Lupetti M Danesi R Del Tacca M Nardi M Effect of low molecular weight heparan sulphate in angiogenesis in the rat corneal after chemical cauterization J Ocul Pharmacol 1994 10 273 8
142. Lund EL Olsen MW Lipson KE McMahon G Howlett AR Kristjansen PEG Improved effect of an anti-angiogenic tyrosine kinase inhibitor (SU5416) by combinations with fractionated radiotherapy or low molecular weight heparin Neoplasia 2003 5 155 60
143. Kragh M Loechel F Non-anti-coagulant heparins: a promising approach for prevention of tumor metastasis Int J Oncol 2005 27 1159 67
144. Lapierre F Holme K lam L Tressler RJ Storm N Wee J Stack RJ Castellot J Tyrell DJ Chemical modifications of heparin that diminish its anti-coagulant but preserve its hepraranase-inhibitor, angiostatic, anti-tumor and anti-metastatic properties Glycobiology 1996 6 355 66
145. Casu B Guerrini M Guglieri S Naggi A Perez M Torri G Cassinelli G Rabatti D Carminati P Gianninni G Penco S Pisano C Belleri M Rusnati M Presta M Undersulfated and glycol-split heparins endowed with anti-angiogenic activity J Med Chem 2004 47 838 48
146. Casu B Guerrini M Naggi A Perez M Torri G Ribatti D Carminati P Gianni G Penco S Pisano C Belleri M Rusnati M Presta M Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors Biochemistry 2002 41 10519 28
147. Presta M Oreste P Zoppetti G Belleri M Tanghetti E Leali D Urbinati C Bugatti A Roncha R Nicoli S Moroni E Stablie H Camozzi M Hernandez GA Mitola S Dell'Era P Rusnati M Ribatti D Anti-angiogenic activity of semisynthetic biotechnological heparins. Low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists Arterioscler Thromb Vasc Biol 2005 25 71 6
148. Presta M Leali D Stabile H Ronca R Camozzi M Coco L Moroni E Liekens S Rusnati M Heparin derivatives as angiogenesis inhibitors Curr Pharmaceut Design 2003 9 553 66
149. Kakkar AK Low- and ultra-low-molecular-weight heparins Best Pract Res Clin Haematol 2004 17 77 87
150. Jayson GC Gallagher JT Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells Br J Cancer 1997 75 9 16
151. Norrby K Human apo-lactoferrin enhances angiogenesis mediated by vascular endothelialgrowth factor A in vivo J Vasc Res 2004 41 293 304
152. Qi J Kreutzer DL Fibrin activation of vascular endothelial cells: induction of IL-8 expression J Immunol 1995 155 867 76
153. Karumanchi SA Jha V Ramchandran R Karihaloo A Tsiokas L Chan B Dhanabal M Hanai JI Venkataraman G Shiver Z Keiser N Kalluri R Zeng H Mukhopadhyay D Chen RL Lander AD Hagihara K Yamaguchi Y Sasisekharan R Cantley L Sukhatme VP Cell surface glypicans are low-affinity endostatin receptors Mol Cell 2001 7 811 22
154. Wickstrom SA Alitalo K Keski-Oja J Endostatin associates with lipid rafts and induces reorganization of the actin cytoskeleton via down-regulation of RhoA activity J Biol Chem 2003 278 37895 901